(Source: Pall Corporation) – An update on Transmissible Spongiform Encephalopathies (TSEs), including variant Creutzfeldt-Jakob Disease (vCJD), the human form of Mad Cow Disease, was a key topic at the Food & Drug Administration’s Blood Products Advisory Committee meeting in Gaithersburg, Maryland yesterday.
Issues such as the number of people that could be harboring vCJD as carriers, the impact on the blood supply and new risk reduction measures were addressed. The Pall Corporation presented an overview of their research on prion reduction technology as a new risk reduction measure to help prevent transfusion transmission of infectious prions that can cause vCJD. The Company expects to launch the new filter commercially in Europe this spring.
